Rubaba Hussain, MD
Family Medicine · Clark, NJNPI 1194913681
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $776 of the $1,234 with a category attached, or 62.9%. Alnylam Pharmaceuticals Inc. accounts for 67.4% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2023 at $980 and has fallen 84.6% since, to $151 in 2025.
Across 15 payments — averaging $82.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alnylam Pharmaceuticals Inc.$832
- Merz North America, Inc.$220
- Novo Nordisk$120
- Merck$31
- C. R. Bard, Inc. & Subsidiaries$30
Across 787 payments — averaging $4881.84 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1.1M
- Pfizer$861K
- Alnylam Pharmaceuticals Inc.$408K
- Cue Health Inc.$396K
- Sanofi Pasteur Inc.$287K
- GSK$252K
- plus $549K from 10 others
What the payments were for
- Travel & lodging$45837%
- Food & beverage$77663%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alnylam Pharmaceuticals Inc. | 8 | $832 |
| Merz North America, Inc. | 3 | $220 |
| Novo Nordisk | 1 | $120 |
| Merck | 1 | $31 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,234 in reported general payments places this provider in the 70th percentile of 2,084 family medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Albuterol Sulfate HfaAlbuterol Sulfate | 18 | $541 |
| Fluticasone Propionate | 25 | $157 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 12 | $135 |
| Azithromycin | 23 | $97 |
| Ibuprofen | 31 | $55 |
| Amoxicillin | 12 | $27 |
| Prednisone | 19 | $9 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Clark
- Mikhail VarshavskiChatham$1.4M
- Janet ColeFar Hills$466K
- Matthew PintoMarlton$239K
- Jennifer CaudleSewell$226K
- Jeffrey LevineNew Brunswick$195K
- Jennifer AmicoNew Brunswick$159K
- Dena LacaraFairfield$122K
- Gaurang BrahmbhattHoboken$89K
- Juan LatorreHoboken$71K
- Sally MravcakJersey City$64K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.